Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Blankenstein

Showing results (41-50 of 138) with videos related to

Pageof 14
Sort By:
International Journal of Cancer|March 10, 2005
Necrotic death but not irradiation abolishes costimulation of T-cell effector functions and survival by CD80-expressing tumor cellsLilian Stärck, Christian Scholz, Thomas Blankenstein, et al.
International Journal of Cancer|August 24, 2017
The immune system prevents recurrence of transplanted but not autochthonous antigenic tumors after oncogene inactivation therapyKathleen Anders, Olivia Kershaw, Lionel Larue, et al.
Cancer Research|May 23, 2002
Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumorsZhihai Qin, Christina Harders, Xuetao Cao, et al.
BMC Bioinformatics|September 4, 2019
SigsPack, a package for cancer mutational signaturesFranziska Schumann, Eric Blanc, Clemens Messerschmidt, et al.
European Journal of Immunology|September 8, 2011
Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumorsJehad Charo, Cynthia Perez, Christian Buschow, et al.
Histology and Histopathology|September 25, 2010
The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomasAnsgar Brüning, Julia Jückstock, Thomas Blankenstein, et al.
Journal for Immunotherapy of Cancer|October 27, 2022
H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2<sup>+</sup> patients with diffuse midline gliomaLena Immisch, George Papafotiou, Oliver Popp, et al.
Cancer Research|March 30, 2013
Fibroblast-specific protein 1/S100A4-positive cells prevent carcinoma through collagen production and encapsulation of carcinogensJinhua Zhang, Lin Chen, Xiaoman Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
T-cell Receptors for Clinical Therapy: <i>In Vitro</i> Assessment of Toxicity RiskAndre Kunert, Matthias Obenaus, Cor H J Lamers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2018
Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell PolyomavirusIoannis Gavvovidis, Matthias Leisegang, Gerald Willimsky, et al.
Pageof 14

Showing results (41-50 of 138) with videos related to

Sort By:
Pageof 14
International Journal of Cancer|March 10, 2005
Necrotic death but not irradiation abolishes costimulation of T-cell effector functions and survival by CD80-expressing tumor cellsLilian Stärck, Christian Scholz, Thomas Blankenstein, et al.
International Journal of Cancer|August 24, 2017
The immune system prevents recurrence of transplanted but not autochthonous antigenic tumors after oncogene inactivation therapyKathleen Anders, Olivia Kershaw, Lionel Larue, et al.
Cancer Research|May 23, 2002
Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumorsZhihai Qin, Christina Harders, Xuetao Cao, et al.
BMC Bioinformatics|September 4, 2019
SigsPack, a package for cancer mutational signaturesFranziska Schumann, Eric Blanc, Clemens Messerschmidt, et al.
European Journal of Immunology|September 8, 2011
Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumorsJehad Charo, Cynthia Perez, Christian Buschow, et al.
Histology and Histopathology|September 25, 2010
The metastasis-associated gene MTA3 is downregulated in advanced endometrioid adenocarcinomasAnsgar Brüning, Julia Jückstock, Thomas Blankenstein, et al.
Journal for Immunotherapy of Cancer|October 27, 2022
H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2<sup>+</sup> patients with diffuse midline gliomaLena Immisch, George Papafotiou, Oliver Popp, et al.
Cancer Research|March 30, 2013
Fibroblast-specific protein 1/S100A4-positive cells prevent carcinoma through collagen production and encapsulation of carcinogensJinhua Zhang, Lin Chen, Xiaoman Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
T-cell Receptors for Clinical Therapy: <i>In Vitro</i> Assessment of Toxicity RiskAndre Kunert, Matthias Obenaus, Cor H J Lamers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2018
Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell PolyomavirusIoannis Gavvovidis, Matthias Leisegang, Gerald Willimsky, et al.
Pageof 14